BioSpace News Archive

OcuTerra Therapeutics, Inc . today announced the appointment of David J. Tanzer, MD, as Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs.

SureCo, a leader in pioneering health care solutions, purchases telemedicine network and platform, Tembi Health

Pipeline Therapeutics today announced that Scott Oross has been appointed as General Counsel.

Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, a t the International Liver Congress (ILC) ™ 2021.

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union

Veru Inc. today announced that it has enrolled the first patient in its Phase 3 VERACITY clinical trial of sabizabulin, an oral, first-in-class, new chemical entity, androgen receptor transport disruptor (targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus), for metastatic castration and androgen receptor targeting agent resistant prostate cancer.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for RINVOQ ® (upadacitinib) for the treatment of adults with active psoriatic arthritis.

CEL-SCI Corporation invites participants to pre-submit questions for the Company’s upcoming Annual Shareholder Meeting to be held on July 1, 2021 at 10:00 a.m. EDT.

Lyndra Therapeutics today announced results from a preclinical study on LYN-013, the company’s oral, ultra-long-acting, extended-release (ER) buprenorphine capsule, in development for the weekly treatment of opioid use disorder (OUD).

CeQur ® , a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the appointments of Rick Doubleday and Meret Gaugler, Ph.D., to its Board of Directors.